Your session is about to expire
← Back to Search
Other
Protein Intake for Healthy Subjects
N/A
Recruiting
Led By Glenda Courtney-Martin, PhD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will determine if increasing protein intake above the current recommended DRI produces increases in the GSH synthesis rates in erythrocytes, which protect cells from damage.
Who is the study for?
This trial is for healthy children over 22 kg, young adults aged 19-40 with a BMI under 25, and older adults aged 60-90 in good health with normal blood markers. Participants must be willing to have their diet and protein intake controlled and provide consent. Those on weight loss diets, with recent significant weight loss, chronic diseases affecting metabolism or unwilling to have blood drawn are excluded.
What is being tested?
The study aims to understand how different levels of protein intake affect the production of Glutathione (GSH), an important antioxidant in our cells. Healthy participants will consume diets formulated with varying amounts of protein to see if higher intakes boost GSH synthesis rates in red blood cells across different age groups.
What are the potential side effects?
Since this trial involves dietary changes rather than medication, side effects may include digestive discomfort due to new diet regimens. However, no specific side effects related to medications are expected as it's not a drug trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Erythrocyte GSH Fractional synthesis rates
Secondary study objectives
Erythrocyte GSH absolute synthesis
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Protein intakeExperimental Treatment1 Intervention
Varying protein intakes.
Find a Location
Who is running the clinical trial?
The Hospital for Sick ChildrenLead Sponsor
712 Previous Clinical Trials
6,959,681 Total Patients Enrolled
Glenda Courtney-Martin, PhDPrincipal InvestigatorAcademic &Clinical Specialist
5 Previous Clinical Trials
111 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have lost a lot of weight in the past month.You have lost a lot of weight in the past month or are following a diet to intentionally lose weight.You have a long-term illness or recent sickness that affects how your body processes certain substances. This includes conditions like HIV, diabetes, cancer, liver or kidney disease, and having a cold or flu.You cannot handle or tolerate the diet.You cannot handle or tolerate certain types of food.We are looking for both young and old adults who are in good health.You are currently following a diet to lose weight.You are currently taking medications that can affect certain chemical processes in the body, like acetaminophen or steroids.You drink more than 2 cups of coffee per day.You drink more than one alcoholic drink per day, like a beer or a half glass of wine.You are willing to take part in the study.You are a young adult who is in good health.
Research Study Groups:
This trial has the following groups:- Group 1: Protein intake
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.